Antibody Drug Conjugates Market: Industry Expert View on Future Growth and Market Trends
The growth of antibody drug conjugates market is attributed to driving factors, such as the growing strategic partnerships to develop of antibody drug conjugates, rising incidences of cancer cases, and increasing FDA approvals for ADCs. Whereas the high cost of ADCs development and commercialization is hindering market growth.
Several companies operating in the market are taking strategic initiatives, such as enhancing product offerings with advanced technologies. For instance, in August 2023, ADC Therapeutics SA announced that two ZYNLONTA (loncastuximab tesirine-lpyl) abstracts have been accepted for presentation at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023). The data show signs of durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma. Such strategic decisions are expected to enhance product and technology development by the companies and contribute significantly to market growth.
The antibody drug conjugates market comprises top players such as ADC Therapeutics SA, Pfizer Inc., F. Hoffmann-La Roche Ltd, ImmunoGen, Inc., GSK Plc, Gilead Sciences Inc., AstraZeneca Plc, Astellas Pharma Inc., RemeGen Co Ltd, Takeda Pharmaceutical Co Ltd, and others. The companies listed above are implementing various strategies that have resulted in the company's growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the antibody drug conjugates market:
Feb-2023:
Several companies operating in the market are taking strategic initiatives, such as enhancing product offerings with advanced technologies. For instance, in August 2023, ADC Therapeutics SA announced that two ZYNLONTA (loncastuximab tesirine-lpyl) abstracts have been accepted for presentation at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023). The data show signs of durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma. Such strategic decisions are expected to enhance product and technology development by the companies and contribute significantly to market growth.
The antibody drug conjugates market comprises top players such as ADC Therapeutics SA, Pfizer Inc., F. Hoffmann-La Roche Ltd, ImmunoGen, Inc., GSK Plc, Gilead Sciences Inc., AstraZeneca Plc, Astellas Pharma Inc., RemeGen Co Ltd, Takeda Pharmaceutical Co Ltd, and others. The companies listed above are implementing various strategies that have resulted in the company's growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the antibody drug conjugates market:
Feb-2023:
Gilead Sciences, Inc. announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The approval is based on overall survival data from the Phase 3 TROPiCS-02 study.
AstraZeneca and KYM Biosciences Inc. entered into a global exclusive license agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancer. Under the licence agreement, AstraZeneca will be responsible for the research, development, manufacture, and commercialization of CMG901 globally.
Oct-2022:
AstraZeneca and KYM Biosciences Inc. entered into a global exclusive license agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancer. Under the licence agreement, AstraZeneca will be responsible for the research, development, manufacture, and commercialization of CMG901 globally.
Oct-2022:
The US Food and Drug Administration (FDA) approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify metastatic breast cancer patients with low HER2 expression for whom Roche's Enhertu (fam-trastuzumab deruxtecan-nxki) may be considered as a targeted treatment. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC).
About Us:
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Chemicals and Materials.
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Chemicals and Materials.
Comments
Post a Comment